Hikari Dx

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Hikari Dx sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials none currently recruiting 3 completed upper quartile by trial count

Hikari Dx: 4 sponsored US clinical trials, none currently recruiting.

Hikari Dx sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. The most-studied condition in this pipeline is Antiplatelet Therapy, with 1 trials.

Upper-quartile sponsor footprint

Hikari Dx sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

4 total, page 1 of 1

ACTIVE NOT RECRUITING

Clinical Validation of the RENISCHEM L-FABP POC Assay

NCT04864847
COMPLETED

T-TAS® wS Method Comparison

NCT06710262
COMPLETED

Clinical Performance Evaluation of T-TAS®01 HD Chip

NCT06087198
COMPLETED

Clinical Performance Evaluation of T-TAS 01 PL Chip

NCT03621020

Therapeutic Areas

Antiplatelet Therapy 1
Contrast Induced Nephropathy 1
Von Willebrand Disease (VWD) 1
Acute Kidney Injury 1
Healthy Donors 1

How the Hikari Dx archive is shaped

4 indexed studies, none listed as recruiting (0% open); 3 completed (75%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Antiplatelet Therapy (1 trial), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Hikari Dx: archived-pipeline peers nationwide

Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Hikari Dx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Hikari Dx4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action Lab10xBio22nd Century Group23andMe3-C Institute for Social Development
Hikari Dx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Hikari Dx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Hikari Dx page

4 registered trials is a research-attention snapshot, not an endorsement of Hikari Dx or any single study.

  • None of Hikari Dx's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Antiplatelet Therapy is the condition Hikari Dx studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Antiplatelet Therapy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Hikari Dx pipeline card: 4 registered trials from official public datasets.Report a data error.